FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report

FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet